124276-34-2

Usage

Uses

Used in Organic Synthesis:
1-(3-Chlorophenyl)cyclopropanecarboxylic acid is used as a building block in organic synthesis for the creation of various biologically active molecules. Its unique structure and functional groups allow for the development of new compounds with potential applications in various fields.
Used in Pharmaceutical Research:
In pharmaceutical research, 1-(3-Chlorophenyl)cyclopropanecarboxylic acid is utilized as a key intermediate for the synthesis of new drugs. Its structural features contribute to the discovery and development of innovative therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Development:
1-(3-Chlorophenyl)cyclopropanecarboxylic acid also has potential applications in the agrochemical industry. It can be used as a precursor for the synthesis of novel agrochemicals, such as pesticides and herbicides, with enhanced performance and reduced environmental impact.
Used as a Reagent in Chemical Reactions:
Due to its reactive functional groups, 1-(3-Chlorophenyl)cyclopropanecarboxylic acid can be employed as a reagent in various chemical reactions. It can facilitate the formation of new chemical bonds and contribute to the synthesis of complex organic compounds.
Used as a Precursor for Other Organic Compounds:
1-(3-Chlorophenyl)cyclopropanecarboxylic acid serves as a valuable precursor for the production of other organic compounds. Its versatile structure allows for further functionalization and modification, leading to the creation of a wide range of chemical entities with diverse applications.

InChI:InChI=1/C10H9ClO2/c11-8-3-1-2-7(6-8)10(4-5-10)9(12)13/h1-3,6H,4-5H2,(H,12,13)

Upstream product

• 1529-41-5 3-chloro-benzeneacetonitrile 
• 124276-32-0 1-(3-chloro-phenyl)cyclopropanecarbonitrile 

Downstream Products

• 501698-47-1 1-(3-chlorophenyl)cyclopropanecarbonyl chloride 
• 943118-81-8 methyl 1-(3-chlorophenyl)cyclopropanecarboxylate 
• 98480-33-2 (1-(3-chlorophenyl)cyclopropyl)methanol 
• 1252641-14-7 (4R)-1-{[1-(3-chlorophenyl)cyclopropyl]carbonyl}-4-[(2-chlorophenyl)sulfonyl]-N-(1-cyanocyclopropyl)-L-prolinamide 
• 1252638-93-9 (4R)-1-{[1-(3-chlorophenyl)cyclopropyl]carbonyl}-4-{[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]sulfonyl}-N-(1-cyanocyclopropyl)-L-prolinamide 

Relevant academic research and scientific papers

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Rhodium-Catalyzed Enantioselective Silylation of Cyclopropyl C?H Bonds

Hydrosilyl ethers, generated in situ by the dehydrogenative silylation of cyclopropylmethanols with diethylsilane, undergo asymmetric, intramolecular silylation of cyclopropyl C?H bonds in high yields and with high enantiomeric excesses in the presence of

Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8- (trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury

Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure-activity studies in this series by branching at the α position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.

Methods and Compositions for Selectin Inhibition

The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists

A heteroaryl-pyrazole compound of formula (I) or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The present invention also provides a method for preparing the inventive heteroaryl-pyrasole compounds or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders.